29540-0

Delete

Print full article

FDA approves generic canine anti-anxiety medication

Clomipramine hydrochloride helps treat separation anxiety in dogs

Suggested Veterinary Products

Veterinarians in need of a generic drug for their anxious canine patients are in luck.

The first generic form of clomipramine hydrochloride tablets, which are used to treat separation anxiety in dogs older than six months, has been approved by the U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM).

To obtain approval for a generic animal drug, the sponsor of its abbreviated new animal drug application (ANADA) must show the generic product is bioequivalent to the reference listed new animal drug (in this case, Clomicalm), which has been shown to be safe and effective.

For this ANADA, one in vivo blood-level study was conducted. The results demonstrated a product bioequivalence between a generic 20-mg clomipramine hydrochloride tablet and a 20-mg Clomicalm tablet.

Canine behavior problems are diagnosed in an estimated 20 to 40 percent of dogs referred to behavior practices in North America, CVM says. Further, in a survey of factors associated with surrendering dogs to a humane society, three out of 10 of the most commonly reported problems were consistent with separation anxiety.

Clomipramine hydrochloride tablets are available by prescription only and are packaged in color-coded bottles of 30 tablets in 5 mg, 20 mg, 40 mg, and 80 mg doses.

Leave a Comment

Comments

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.